Skip to main content
main-content

Heart failure

07-10-2021 | SGLT2 inhibitors | News

Real-world data back SGLT2 inhibitor benefits even for people initially free of CVD

A real-world study shows a reduced risk for heart failure hospitalization, even in people without pre-existing cardiovascular disease, with use of SGLT2 inhibitors versus GLP-1 receptor agonists.

30-09-2021 | EASD 2021 | Conference coverage | News

AF, PAD, diabetes prevention data reported from DAPA-CKD

The latest DAPA-CKD data show the large absolute benefits of dapagliflozin treatment in people with peripheral artery disease or atrial fibrillation, and that the medication may reduce the risk for type 2 diabetes in people with initial prediabetes.

20-09-2021 | Heart failure | News

Gestational diabetes may flag early HF risk

The presence of gestational diabetes mellitus may identify women at an increased risk for experiencing hospitalization for heart failure within the next few years, research suggests.

29-08-2021 | ESC 2021 | Conference coverage | News

Empagliflozin has broad beneficial effect on HFpEF outcomes

Empagliflozin treatment produces significant reductions in the risk for a broad range of inpatient and outpatient heart failure outcomes in people with a preserved ejection fraction, shows further analysis of EMPEROR-Preserved.

29-08-2021 | ESC 2021 | Conference coverage | News

HF and CKD doubly dangerous for people with type 2 diabetes

Rates of hospitalization and mortality are increased in people with type 2 diabetes who also have heart failure or chronic kidney disease, and more so if they have both conditions, say researchers.

27-08-2021 | ESC 2021 | Conference coverage | News

EMPEROR-Preserved: A win for empagliflozin in HFpEF

Empagliflozin has become the first medication to demonstrate a clear protective effect in people with heart failure and preserved ejection fraction, report the EMPEROR-Preserved investigators.

27-08-2021 | ESC 2021 | Conference coverage | News

Dapagliflozin may reduce risk for ventricular arrhythmias, sudden death

Post-hoc analysis of the DAPA-HF data suggests that dapagliflozin may protect people with heart failure against serious ventricular arrhythmias, cardiac arrest, and sudden cardiovascular death.

20-08-2021 | Empagliflozin | News

Empagliflozin receives FDA approval for use in adults with heart failure

Click through to read more on this announcement

Image Credits